Combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer

Abstract

Provided herein are compositions and methods of treating cancer with combinations of cell cycle inhibitors and LSD1 inhibitors. In some aspects, the cell cycle inhibitor is a CDK4/6 inhibitor, e.g., palbociclib. In some aspects, the LSD1 inhibitor is MC2580 or DDP38003. The compositions and methods of the disclosure may be used to treat cancers including, but not limited to, leukemia, lung cancer, melanoma, or breast cancer. The cancers may be, for example, LSD1-inhibitor-resistant and/or comprise cells having a reduced level of p21 expression or a loss of p21 function.

CPC Classifications